• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 5, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Managing architectural distortion on mammography based on MR enhancement

Bioengineer by Bioengineer
May 5, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at 2019 ARRS Annual Meeting

Leesburg, VA, May 5, 2019–High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US) correlate or magnetic resonance imaging (MRI) enhancement suggests follow-up rather than biopsy may be safely performed, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

Management of MG-detected AD varies among practices when tomosynthesis-guided biopsy is not available. The study was conducted to evaluate outcomes of architectural distortion on mammography (MG) with or without a magnetic resonance (MR) correlate.

Unexplained AD on MG cases with subsequent MR were retrospectively reviewed by MG type, biopsy type and cancer results, cancer type, tumor grade, and receptor status. Among the study group of 57 patients, the NPV of MG AD without MR correlate or enhancement was 97.2%. Forty-four of 57 had MG AD without US correlate. Of 12 patients without US but with MR correlate, cancers (25%) were masses on MR, majority of benign findings (58.3%) were nonmass enhancement (NME), and RS/CSL (41.7%) was mass or NME. No MG AD without US or MR correlate was found to be cancer. The NPV of MG AD without US or MR correlate or enhancement was 100%.

The results indicate that follow-up rather than biopsy may be safely performed in cases of MG AD without US and MRI correlate or enhancement, reducing the need for intervention and lowering healthcare costs.

“With 3D tomosynthesis widely incorporated in many practices, MG AD without US or MRI correlate poses a management dilemma to radiologists,” author of the study Vandana Dialani, MD said. “This study is especially important for institutions which do not have tomo-guided biopsy capabilities and may revert to contrast imaging as a next step in managing MG AD. Our study shows that the NPV of MG AD without US correlate or MR enhancement was 100% and follow-up rather than biopsy may be considered.”

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/mammography_architectural_distortion_mr_enhancement.aspx

Tags: Breast CancercancerHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Brain Tumor Study Reveals How Much Surgery Matters in Oligodendroglioma

Brain Tumor Study Reveals How Much Surgery Matters in Oligodendroglioma

October 5, 2026
Radiologists Sound the Alarm on the World Standard for Staging Childhood Liver Cancer

Radiologists Sound the Alarm on the World Standard for Staging Childhood Liver Cancer

October 5, 2026

AI Model Predicts Survival After Surgery for Gastrointestinal Stromal Tumors

October 5, 2026

Immune Booster Cells Show Promise After Checkpoint Blockers in Liver Cancer

October 5, 2026
Please login to join discussion

POPULAR NEWS

  • Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    29 shares
    Share 12 Tweet 7
  • Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

    29 shares
    Share 12 Tweet 7
  • Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

    29 shares
    Share 12 Tweet 7
  • New Scale Measures How Ready Nurse Educators Really Are for the AI Era

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.